Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2020

01-12-2020 | Lung Cancer | Research article

Imaging features and prognostic value of 18F-FDG PET/CT detection of soft-tissue metastasis from lung cancer: a retrospective study

Authors: Tingting Xu, Xinyi Zhang, Shumao Zhang, Chunfeng Liu, Wenhui Fu, Chengrun Zeng, Yue Chen

Published in: BMC Cancer | Issue 1/2020

Login to get access

Abstract

Background

Soft-tissue metastasis (STM) is a relatively rare, but not exceptional, manifestation of lung cancer. The purpose of this study was to evaluate the imaging features of STM from lung cancer using fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT), and assess the impact of STM detected at baseline PET/CT on patient survival.

Methods

Out of 4543 patients with lung cancer who underwent 18F-FDG PET/CT in our hospital between January 2013 and September 2018, 85 were diagnosed with STM (78 at baseline PET/CT and 7 at restaging PET/CT) and included in the imaging study. We conducted a comparative survival analysis between patients with stage 4 lung cancer with and without STM at baseline PET/CT (n = 78 in each group) and performed univariate and multivariate analyses to investigate the factors affecting the prognosis of lung cancer.

Results

A total of 219 lesions were identified by 18F-FDG PET/CT: 215 were detected by PET and 139 by CT. Muscle STM were primarily found in the hip and upper limb muscle, whereas subcutaneous STM were mainly distributed in the chest, abdomen, and back. In 68 patients, STM were found incidentally during routine 18F-FDG PET/CT staging. Isolated STM were detected in 6 patients, whose tumor staging and treatment were affected by PET/CT findings. There were no significant differences in the 1-, 3-, and 5-year survival rates between patients with and without STM at baseline PET/CT. Brain and adrenal metastases, but not STM, were associated with poor prognosis of stage 4 lung cancer.

Conclusions

We described the PET/CT imaging characteristics of STM from lung cancer, and confirmed that PET/CT can detect unsuspected STM to change the staging and treatment of some patients. Our analysis indicates that STM is not a useful prognostic indicator for patients with advanced lung cancer, while brain and adrenal metastases portend a poor prognosis.
Literature
1.
2.
Tamura T, Kurishima K, Nakazawa K, et al. Specific organ metastases and survival in metastatic non-small-cell lung cancer. Mol Clin Oncol. 2015;3(1):217–21.PubMed
3.
4.
Pretorius ES, Fishman EK. Helical CT of skeletal muscle metastases from primary carcinomas. AJR Am J Roentgenol. 2000;174(2):401–4.PubMed
5.
Qiu DA-S, Xu L-Y, Shames S. The value of 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography in the detection and characterization of soft tissue metastasis. Mol Clin Oncol. 2014;2(5):761–6.PubMedPubMedCentral
6.
Sersar SI. Skeletal muscle metastasis secondary to lung Cancer. South Med J. 2009;102(1):14–5.PubMed
7.
Kanaji N, Tadokoro A, Watanabe N, et al. Association of specific metastatic organs with the prognosis and chemotherapeutic response in patients with advanced lung cancer. Respir Investig. 2019;57(5):472–80.PubMed
8.
Koike Y, Hatori M, Kokubun S. Skeletal muscle metastasis secondary to cancer--a report of seven cases. Ups J Med Sci. 2005;110(1):75–83.PubMed
9.
Plaza JA, Perez-Montiel D, Mayerson J, et al. Metastases to soft tissue: a review of 118 cases over a 30-year period. Cancer. 2008;112(1):193–203.PubMed
10.
Stein-Werblowsky R. Skeletal muscle and tumour metastasis. Experientia. 1974;30(4):423–4.PubMed
11.
Strauss JB, Shah AP, Chen SA, et al. Psoas muscle metastases in non-small cell lung cancer. J Thorac Dis. 2012;4(1):83–7.PubMedPubMedCentral
12.
Weiss L. Biomechanical destruction of cancer cells in skeletal muscle: a rate-regulator for hematogenous metastasis. Clin Exp Metastasis. 1989;7(5):483–91.PubMed
13.
Khandelwal AR, Takalkar AM, Lilien DL, et al. Skeletal Muscle Metastases on FDG PET/CT Imaging. Clin Nucl Med. 2012;37(6):575–9.PubMed
14.
So Y, Yi JG, Song I, et al. Detection of skeletal muscle metastasis: torso FDG PET-CT versus contrast-enhanced chest or abdomen CT. Acta Radiol. 2015;56(7):860–6.PubMed
15.
Yilmaz M, Elboga U, Celen Z, et al. Multiple muscle metastases from lung Cancer detected by FDG PET/CT. Clin Nucl Med. 2011;36(3):245–7.PubMed
16.
Arpaci T, Ugurluer G, Akbas T, et al. Imaging of the skeletal muscle metastases. Eur Rev Med Pharmacol Sci. 2012;16(15):2057–63.PubMed
17.
Haygood TM, Wong J, Lin JC, et al. Skeletal muscle metastases: a three-part study of a not-so-rare entity. Skelet Radiol. 2012;41(8):899–909.
18.
Karunanithi S, Soundararajan R, Sharma P, et al. Spectrum of physiologic and pathologic skeletal muscle 18F-FDG uptake on PET/CT. AJR Am J Roentgenol. 2015;205(2):W141–9.PubMed
19.
Kwas HH, Zendah I, Ghedira H. Skeletal muscle metastases from lung cancer. Asian Cardiovasc Thorac Ann. 2013;21(6):741–3.PubMed
20.
Tuoheti Y, Okada K, Osanai T. Skeletal muscle metastases of carcinoma: a Clinicopathological study of 12 cases. Jpn J Clin Oncol. 2004;34(4):210–4.PubMed
21.
Surov A, Hainz M, Holzhausen H-J, et al. Skeletal muscle metastases: primary tumours, prevalence, and radiological features. Eur Radiol. 2010;20(3):649–58.PubMed
22.
Nagao E, Nishie A, Yoshimitsu K. Gluteal muscular and sciatic nerve metastases in advanced urinary bladder carcinoma. Abdom Imaging. 2004;29(5):619–22.PubMed
23.
Batson OV. The function of the vertebral veins and their role in the spread of metastases. Ann Surg. 1940;112(1):138–49.PubMedPubMedCentral
24.
Omar A, Bae S, Arafat W, et al. Site of metastases as prognostic factors in unselected population of stage IV non-small cell lung Cancer. Asian Pac J Cancer Prev. 2018;19(7):1907–10.PubMedPubMedCentral
25.
Sakurai M, Shinkai T, Eguchi K, et al. Prognostic factors in non-small cell lung cancer: multiregression analysis in the National Cancer Center Hospital (Japan). J Cancer Res Clin Oncol. 1987;113(6):563–6.PubMed
26.
Borges M, Sculier JP, Paesmans M, et al. Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer (NSCLC). Lung Cancer. 1996;16(1):21–33.PubMed
27.
Paralkar VR, Li T, Langer CJ. Population characteristics and prognostic factors in metastatic non-small-cell lung cancer: a Fox Chase Cancer Center retrospective. Clin Lung Cancer 9. 2008;9(2):116–21.
28.
Gibson AJW, Li H, D’Sliva A, et al. Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer. Med Oncol. 2018;35(9):117.PubMed
29.
Di Giorgio A, Sammartino P, Cardini CL, et al. Lung cancer and skeletal muscle metastases. Ann Thorac Surg. 2004;78(2):709–11.PubMed
30.
Emmering J, Vogel WV, Stokkel MPM. Intramuscular metastases on FDG PET-CT: a review of the literature. Nucl Med Commun. 2012;33(2):117–20.PubMed
31.
Pfannenberg C, Aschoff P, Schanz S, et al. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer. 2007;43(3):557–64.PubMed
32.
Nocuń A, Chrapko B. Multiple and solitary skeletal muscle metastases on 18F-FDG PET/CT imaging. Nucl Med Commun. 2015;36(11):1091–9.PubMed
33.
Savas K, Pinar KZ, Sevda KS, et al. Haematogenous muscular metastasis of non-small cell lung cancer in F-18 fluorodeoxyglucose positron emission tomography/computed tomography. Contemp Oncol. 2015;19(3):241–5.
34.
Hagi T, Nakamura T, Sugino Y, et al. Is FDG-PET/CT useful for diagnosing pulmonary metastasis in patients with soft tissue sarcoma? Anticancer Res. 2018;38(6):3635–9.PubMed
35.
Glockner JF, White LM, Sundaram M, et al. Unsuspected metastases presenting as solitary soft tissue lesions: a fourteen-year review. Skelet Radiol. 2000;29(5):270–4.
36.
Surov A, Pawelka MK, Wienke A, et al. PET/CT imaging of skeletal muscle metastases. Acta Radiol. 2014;55(1):101–6.PubMed
37.
Sorensen JB, Hansen HH, Hansen M, et al. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol. 1988;6:1474–80.PubMed
38.
Jacot W, Quantin X, Boher JM, et al. Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO analysis of prognostic factors. Br J Cancer. 2001;84:903–9.PubMedPubMedCentral
39.
Sanchez de Cos J, Sojo Gonzalez MA, Montero MV, et al. Non-small cell lung cancer and silent brain metastasis. Survival and prognostic factors. Lung Cancer. 2009;63:140–5.PubMed
40.
Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small-cell lung cancer: an eastern cooperative oncology group study. J Clin Oncol. 1986;4:702–9.PubMed
41.
Bauml J, Mick R, Zhang Y, et al. Determinants of survival in advanced non-small-cell lung cancer in the era of targeted therapies. Clin Lung Cancer. 2013;14:581–91.PubMedPubMedCentral
42.
Saad F, Lipton A, Cook R, et al. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007;110:1860–7.PubMed
43.
Riihimaki M, Hemminki A, Fallah M, et al. Metastatic sites and survival in lung cancer. Lung Cancer. 2014;86:78–84.PubMed
44.
McKay RR, Kroeger N, Xie W, et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol. 2014;65:577–84.PubMed
45.
Riihimaki M, Thomsen H, Hemminki A, et al. Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer. BMC Cancer. 2013;13:36.PubMedPubMedCentral
46.
Hemminki K, Riihimaki M, Sundquist K, et al. Site-specific survival rates for cancer of unknown primary according to location of metastases. Int J Cancer. 2013;133:182–9.PubMed
47.
Li J, Zhu H, Sun L, et al. Prognostic value of site-specific metastases in lung cancer: a population based study. J Cancer. 2019;10:3079–86.PubMedPubMedCentral
48.
Hoang T, Xu R, Schiller JH, et al. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol. 2005;23:175–83.PubMed
49.
50.
Jenne CN, Kubes P. Immune surveillance by the liver. Nat Immunol. 2013;14:996–1006.
51.
Mohammad K, Sadikot RT. Adrenal insufficiency as a presenting manifestation of nonsmall cell lung cancer. South Med J. 2009;102:665–7.PubMed
52.
Kanaji N, Mizoguchi H, Inoue T, et al. Clinical features of patients with lung cancer accompanied by thromboembolism or disseminated intravascular coagulation. Ther Clin Risk Manag. 2018;14:1361–8.PubMedPubMedCentral
53.
Shin D-S, Shon O-J, Han D-S, et al. The clinical efficacy of 18F-FDG-PET/CT in benign and malignant musculoskeletal tumors. Ann Nucl Med. 2008;22(7):603–9.PubMed
54.
Pop D, Nadeemy AS, Venissac N, et al. Skeletal muscle metastasis from non-small cell lung Cancer. J Thorac Oncol. 2009;4(10):1236–41.PubMed
Metadata
Title
Imaging features and prognostic value of 18F-FDG PET/CT detection of soft-tissue metastasis from lung cancer: a retrospective study
Authors
Tingting Xu
Xinyi Zhang
Shumao Zhang
Chunfeng Liu
Wenhui Fu
Chengrun Zeng
Yue Chen
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2020
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-020-07080-0

Other articles of this Issue 1/2020

BMC Cancer 1/2020 Go to the issue

Case report

Huge aneurysmal bone cyst secondary to giant cell tumor of the hand phalanx: a case report and related literature

Research article

Novel bioinformatic classification system for genetic signatures identification in diffuse large B-cell lymphoma

Research article

Dietary factors and risk of mortality among patients with esophageal cancer: a systematic review

Research article

Prognostic and diagnostic value of circRNA expression in colorectal carcinoma: a meta-analysis

Study protocol

Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study

Research article

Comparison of survival outcomes between radio-chemotherapy and radical hysterectomy with postoperative standard therapy in patients with stage IB1 to IIA2 cervical cancer: long-term oncological outcome analysis in 37 Chinese hospitals
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits